Poxel wraps up enrollment in DESTINY-1 phase 2 trial for PXL065 in NASH

Poxel, a French biopharma company, has wrapped up patient enrollment for the phase 2 DESTINY-1 clinical trial, which is evaluating PXL065 for the treatment of ... Read More